Tip
Non-cystic Fibrosis Bronchiectasis
Novartis PharmaceuticalsSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
11 Active assets in the Non-cystic Fibrosis Bronchiectasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ivacaftor Emory University | Phase 4 | BB |
ELEXACAFTOR Emory University | Phase 4 | BB |
Tezacaftor Emory University | Phase 4 | BB |
hsk31858 Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | B |
csl787 CSL Behring | Phase 2 | B |
View all 17 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →